Nebius Group N.V. (NBIS)vsTNL Mediagene Ordinary Shares (TNMG)
NBIS
Nebius Group N.V.
$227.81
+11.93%
COMMUNICATION SERVICES · Cap: $66.16B
TNMG
TNL Mediagene Ordinary Shares
$0.60
-3.24%
COMMUNICATION SERVICES · Cap: $2.09M
Smart Verdict
WallStSmart Research — data-driven comparison
Nebius Group N.V. generates 1667% more annual revenue ($877.90M vs $49.67M). NBIS leads profitability with a 93.1% profit margin vs -167.9%. NBIS earns a higher WallStSmart Score of 55/100 (C-).
NBIS
Buy55
out of 100
Grade: C-
TNMG
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+26.0%
Fair Value
$307.91
Current Price
$227.81
$80.10 discount
Intrinsic value data unavailable for TNMG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 93 of every $100 in revenue as profit
Revenue surging 684.0% year-over-year
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Trading at 8.1x book value
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -164.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIS
The strongest argument for NBIS centers on Profit Margin, Revenue Growth, Market Cap. Profitability is solid with margins at 93.1% and operating margin at -32.1%. Revenue growth of 684.0% demonstrates continued momentum.
Bull Case : TNMG
The strongest argument for TNMG centers on Price/Book.
Bear Case : NBIS
The primary concerns for NBIS are Price/Book, EPS Growth, Debt/Equity. A P/E of 101.0x leaves little room for execution misses.
Bear Case : TNMG
The primary concerns for TNMG are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 23.52 is elevated, increasing financial risk.
Key Dynamics to Monitor
NBIS profiles as a growth stock while TNMG is a turnaround play — different risk/reward profiles.
NBIS carries more volatility with a beta of 1.24 — expect wider price swings.
NBIS is growing revenue faster at 684.0% — sustainability is the question.
TNMG generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
NBIS scores higher overall (55/100 vs 30/100), backed by strong 93.1% margins and 684.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nebius Group N.V.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Nebius Group N.V. (Ticker: NBIS) is a forward-looking technology company specializing in advanced digital solutions designed to enhance client engagement and streamline operational efficiency across diverse sectors. By harnessing the power of cloud computing, artificial intelligence, and data analytics, Nebius equips businesses to effectively manage the complexities of the digital age. With a strong portfolio of intellectual property and meaningful strategic partnerships, the company is poised to capture significant growth opportunities in the dynamic technology landscape, positioning itself as an appealing investment choice for institutional investors seeking high-growth prospects in tech-driven markets.
Visit Website →TNL Mediagene Ordinary Shares
COMMUNICATION SERVICES · PUBLISHING · USA
TNL Mediagene Ordinary Shares is an innovative biopharmaceutical company focused on developing and commercializing advanced medical therapies that target critical unmet needs in oncology and autoimmune disorders. The company boasts a promising pipeline supported by cutting-edge technologies and strategic collaborations, positioning it for significant growth within the competitive healthcare sector. With a strong commitment to scientific excellence and patient-centered solutions, TNL Mediagene is establishing itself as a key player in the biopharmaceutical industry, dedicated to enhancing patient outcomes and addressing challenging health issues.
Visit Website →Compare with Other INTERNET CONTENT & INFORMATION Stocks
Want to dig deeper into these stocks?